GlobeImmune, Inc. Wins Prestigious Technology Honor
LOUISVILLE, Colo., May 22 /PRNewswire/ -- GlobeImmune today announced that it has been named a winner of the prestigious Red Herring 100 award. GlobeImmune was recognized for its pioneering work on yeast-based products called Tarmogens (Targeted Molecular Immunogens) which activate the immune system, including "killer" T cells, to eliminate cancer and infectious diseases.
The Red Herring award recognizes 100 private technology companies in North America who, through ground-breaking "disruptive" technologies, are dedicated to pushing the boundaries of conventional thinking. GlobeImmune's unique Tarmogen platform has already demonstrated activity in a number of disease models. Two products based on the Tarmogen platform are currently being tested in human clinical trials, GI-4000 in pancreas cancer and GI-5005 in hepatitis C.
"With venture capital flowing again, we're seeing a lot of innovative new companies taking on the established players with disruptive technologies and innovative business plans," said Joel Dreyfuss, Editor-in-Chief of Red Herring. "The Red Herring 100 North America companies, among them GlobeImmune, are pushing and breaking the boundaries of the technology business and we are excited to report on their success stories."
"We are honored to be recognized as a pioneer by this award," said Timothy C. Rodell, M.D., GlobeImmune's President and CEO. "With two programs in clinical trials and an influenza vaccine under development, GlobeImmune is working aggressively to develop novel and differentiated medicines for unmet medical needs."
Tarmogens are whole, heat-killed recombinant yeast that are genetically modified to express one or more protein antigens that stimulate the immune system against diseased cells. Tarmogens actively bind to receptors on antigen presenting cells, including Toll-like receptors, and are avidly taken up by these cells that activate the immune system, stimulating an immune response to kill diseased cells.
GlobeImmune, Inc. is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapy products called Tarmogens for the treatment of cancer and infectious diseases. The Company's lead product series, GI-4000 for the treatment of cancers of the lung and gastrointestinal tract, is currently in Phase 2 clinical trials. GlobeImmune has an ongoing Phase 1b trial for its second product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection. For additional information, please visit the company's website at www.globeimmune.com.
About Red Herring's 100 North America Award
Red Herring's lists of top private companies are an important part of the renowned magazine's tradition of identifying new and innovative technology firms and entrepreneurs. Companies like Google and eBay were spotted in their early days by Red Herring editors as some that would change the way we live and work.
After receiving more than 1,000 submissions and nominations, Red Herring's editorial staff rigorously evaluated GlobeImmune and the other contenders through a careful analysis of financial data and subjective criteria, including quality of management, execution of strategy, and dedication to research and development. The Red Herring 100 North America companies are at the forefront of the technologies that are changing our lives in profound ways.
About Red Herring Magazine
Red Herring magazine is a sophisticated insider's guide to the business of technology, featuring unparalleled insights on the emerging technologies driving the economy, from the Internet to wireless communications and digital entertainment. Red Herring's journalists report on how innovation and entrepreneurship are transforming business and how the business of technology is transforming the world, providing readers with a deep understanding of venture capital and capital markets. Recognized as an essential resource in today's fast-changing business world, Red Herring gets the right answers before anyone else even thinks to ask the questions. More information on Red Herring is available on the internet at www.redherring.com.
This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs. Actual results could differ materially from those projected and the Company cautions investors not to place undue reliance on the forward-looking statements contained in this release.GlobeImmune, Inc.
CONTACT: Kirk Christoffersen, Senior Director, Corporate Development ofGlobeImmune, Inc., +1-303-625-2700, email@example.com; or SabrinaOei, President of Sabra Communications, +1-303-808-9168,firstname.lastname@example.org, for GlobeImmune, Inc.